Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025
Agios Pharmaceuticals (Nasdaq: AGIO), a company specializing in cellular metabolism and PK activation therapies for rare diseases, has announced its upcoming participation in the TD Cowen 45th Annual Healthcare Conference. The company's management team will deliver a presentation on Monday, March 3, 2025, at 10:30 a.m. ET.
The presentation will be accessible through a live webcast on the Investors section of Agios's website (www.agios.com) under the Events & Presentations tab. Interested parties who cannot attend the live presentation can access a replay of the webcast, which will remain available on the company's website for a minimum of two weeks following the event.
Agios Pharmaceuticals (Nasdaq: AGIO), un'azienda specializzata nelle terapie per il metabolismo cellulare e l'attivazione della PK per malattie rare, ha annunciato la sua prossima partecipazione alla 45ª Conferenza Annuale sulla Salute TD Cowen. Il team di gestione dell'azienda presenterà un intervento lunedì 3 marzo 2025, alle 10:30 a.m. ET.
La presentazione sarà accessibile tramite un webcast dal vivo nella sezione Investitori del sito web di Agios (www.agios.com) sotto la scheda Eventi e Presentazioni. Le parti interessate che non possono partecipare alla presentazione dal vivo potranno accedere a una registrazione del webcast, che rimarrà disponibile sul sito dell'azienda per un minimo di due settimane dopo l'evento.
Agios Pharmaceuticals (Nasdaq: AGIO), una empresa especializada en terapias de metabolismo celular y activación de PK para enfermedades raras, ha anunciado su próxima participación en la 45ª Conferencia Anual de Salud de TD Cowen. El equipo de gestión de la empresa realizará una presentación el lunes 3 de marzo de 2025, a las 10:30 a.m. ET.
La presentación será accesible a través de un webcast en vivo en la sección de Inversores del sitio web de Agios (www.agios.com) en la pestaña Eventos y Presentaciones. Las partes interesadas que no puedan asistir a la presentación en vivo podrán acceder a una repetición del webcast, que permanecerá disponible en el sitio web de la empresa durante un mínimo de dos semanas después del evento.
Agios Pharmaceuticals (Nasdaq: AGIO), 희귀 질환을 위한 세포 대사 및 PK 활성화 치료를 전문으로 하는 회사가 TD Cowen 제45회 연례 헬스케어 컨퍼런스에 참석할 예정이라고 발표했습니다. 회사의 경영진은 2025년 3월 3일 월요일 오전 10시 30분 ET에 발표를 진행할 것입니다.
발표는 Agios 웹사이트의 투자자 섹션(www.agios.com)에서 이벤트 및 발표 탭 아래의 실시간 웹캐스트를 통해 접근할 수 있습니다. 라이브 발표에 참석할 수 없는 이해관계자는 이벤트 이후 최소 2주 동안 회사 웹사이트에서 이용 가능한 웹캐스트 재생을 통해 접근할 수 있습니다.
Agios Pharmaceuticals (Nasdaq: AGIO), une entreprise spécialisée dans les thérapies de métabolisme cellulaire et d'activation de PK pour les maladies rares, a annoncé sa prochaine participation à la 45ème Conférence Annuelle sur la Santé de TD Cowen. L'équipe de direction de l'entreprise présentera une intervention le lundi 3 mars 2025, à 10h30 ET.
La présentation sera accessible via un webcast en direct dans la section Investisseurs du site web d'Agios (www.agios.com) sous l'onglet Événements et Présentations. Les parties intéressées qui ne peuvent pas assister à la présentation en direct pourront accéder à un enregistrement du webcast, qui restera disponible sur le site de l'entreprise pendant un minimum de deux semaines après l'événement.
Agios Pharmaceuticals (Nasdaq: AGIO), ein Unternehmen, das sich auf Zellstoffwechsel- und PK-Aktivierungstherapien für seltene Krankheiten spezialisiert hat, hat seine bevorstehende Teilnahme an der 45. Jahreskonferenz im Gesundheitswesen von TD Cowen angekündigt. Das Managementteam des Unternehmens wird am Montag, den 3. März 2025, um 10:30 Uhr ET eine Präsentation halten.
Die Präsentation wird über einen Live-Webcast im Investorenbereich der Agios-Website (www.agios.com) unter dem Reiter Veranstaltungen und Präsentationen zugänglich sein. Interessierte, die nicht an der Live-Präsentation teilnehmen können, haben die Möglichkeit, eine Wiederholung des Webcasts anzusehen, der mindestens zwei Wochen nach der Veranstaltung auf der Unternehmenswebsite verfügbar bleibt.
- None.
- None.
CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025, at 10:30 a.m. ET.
The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.
About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.
Contacts:
Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com
Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
Media@agios.com
FAQ
When is Agios Pharmaceuticals (AGIO) presenting at the TD Cowen Healthcare Conference 2025?
How can investors watch AGIO's presentation at the TD Cowen Conference 2025?
How long will AGIO's TD Cowen Conference presentation replay be available?
What is the focus area of Agios Pharmaceuticals (AGIO)?
